About the Authors
- Caterina Vacchi-Suzzi
-
Affiliation Discovery and Investigative Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland
- Yasmina Bauer
-
Affiliation Translational Science Biology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
- Brian R. Berridge
-
Affiliation Safety Assessment, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America
- Sandrine Bongiovanni
-
Affiliation Biomarker Development, Novartis Institutes for Biomedical Research, Basel, Switzerland
- Kevin Gerrish
-
Affiliation National Institute of Environmental Health Science, National Institutes of Health, Research Triangle Park, North Carolina, United States of America
- Hisham K. Hamadeh
-
Affiliation Comparative Biology and Safety Sciences, Amgen Inc., Thousand Oaks, California, United States of America
- Martin Letzkus
-
Affiliation Biomarker Development, Novartis Institutes for Biomedical Research, Basel, Switzerland
- Jonathan Lyon
-
Affiliation Investigative Preclinical Toxicology, GlaxoSmithKline, Ware, United Kingdom
- Jonathan Moggs
-
Affiliation Discovery and Investigative Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland
- Richard S. Paules
-
Affiliation National Institute of Environmental Health Science, National Institutes of Health, Research Triangle Park, North Carolina, United States of America
- François Pognan
-
Affiliation Discovery and Investigative Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland
- Frank Staedtler
-
Affiliation Biomarker Development, Novartis Institutes for Biomedical Research, Basel, Switzerland
- Martin P. Vidgeon-Hart
-
Affiliation Investigative Preclinical Toxicology, GlaxoSmithKline, Ware, United Kingdom
- Olivier Grenet
-
Affiliation Discovery and Investigative Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland
- Philippe Couttet
-
* E-mail: philippe.couttet@novartis.com
Affiliation Discovery and Investigative Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland
Competing Interests
The authors have read the journal’s policy and have the following conflicts: Authors Dr. Vacchi-Suzzi, Dr. Moggs, Dr. Pognan, Dr. Grenet, Dr. Couttet, Dr. Bongiovanni, Dr. Letzkus and Dr. Staedtler are employed by Novartis Institutes for Biomedical Research. Dr. Bauer is employed by Actelion Pharmaceuticals Ltd. Dr. Berridge, Dr. Lyon and Dr. Vidgeon-Hart are employed by GlaxoSmithKline. Dr. Hamadeh is employed by Amgen Inc. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: HH JL RP PC CVS. Performed the experiments: BRB ML MPV-H CVS. Analyzed the data: YB KG HH CVS. Contributed reagents/materials/analysis tools: SB FS. Wrote the paper: CVS KG PC. Supervised the study and experimental design, helped interpretation of the data: CVS PC JM OG FP YB KG HH JL RP NH FS. Reviewed and commented on the manuscript: CVS YB BRB SB KG HH ML JL JM RP FP FS MPV-H OG PC.